Richard Friedman to Fibrinolytic Agents
This is a "connection" page, showing publications Richard Friedman has written about Fibrinolytic Agents.
Connection Strength
0.767
-
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep; 126(3):175-82.
Score: 0.286
-
Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009 Sep-Oct; 15 Suppl 1:25S-31S.
Score: 0.271
-
Extended thromboprophylaxis after hip or knee replacement. Orthopedics. 2003 Feb; 26(2 Suppl):s225-30.
Score: 0.173
-
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 Mar; 83(3):336-45.
Score: 0.038